Ma CX - Search Results

1

Acquired HER2 mutations in ER⁺ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.

Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, Winer EP, Lin NU, Wagle N. Nayar U, et al. Among authors: ma cx. Nat Genet. 2019 Feb;51(2):207-216. doi: 10.1038/s41588-018-0287-5. Epub 2018 Dec 10. Nat Genet. 2019. PMID: 30531871

2

Neoadjuvant endocrine therapy for locally advanced breast cancer.

Ma CX, Ellis MJ. Ma CX, et al. Semin Oncol. 2006 Dec;33(6):650-6. doi: 10.1053/j.seminoncol.2006.08.013. Semin Oncol. 2006. PMID: 17145344 Review.

3

Predicting endocrine therapy responsiveness in breast cancer.

Ma CX, Sanchez CG, Ellis MJ. Ma CX, et al. Oncology (Williston Park). 2009 Feb;23(2):133-42. Oncology (Williston Park). 2009. PMID: 19323294 Free article. Review.

4

Neoadjuvant endocrine therapy for breast cancer.

Chawla JS, Ma CX, Ellis MJ. Chawla JS, et al. Among authors: ma cx. Surg Oncol Clin N Am. 2010 Jul;19(3):627-38. doi: 10.1016/j.soc.2010.04.004. Surg Oncol Clin N Am. 2010. PMID: 20620931 Review.

5

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.

Ma CX, Crowder RJ, Ellis MJ. Ma CX, et al. Steroids. 2011 Jul;76(8):750-2. doi: 10.1016/j.steroids.2011.02.023. Epub 2011 Mar 21. Steroids. 2011. PMID: 21420991 Review.

6

Estrogen and progesterone receptors in breast cancer.

Ma CX. Ma CX. Clin Adv Hematol Oncol. 2011 May;9(5):385-6. Clin Adv Hematol Oncol. 2011. PMID: 21685867 No abstract available.

7

Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer.

Goncalves R, Ma C, Luo J, Suman V, Ellis MJ. Goncalves R, et al. Nat Rev Clin Oncol. 2012 Feb 28;9(4):223-9. doi: 10.1038/nrclinonc.2012.21. Nat Rev Clin Oncol. 2012. PMID: 22371132 Free PMC article. Review.

8

Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.

Roop RP, Ma CX. Roop RP, et al. Among authors: ma cx. Future Oncol. 2012 Mar;8(3):273-92. doi: 10.2217/fon.12.8. Future Oncol. 2012. PMID: 22409464 Review.

9

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. Carey LA, et al. Among authors: ma cx. J Clin Oncol. 2012 Jul 20;30(21):2615-23. doi: 10.1200/JCO.2010.34.5579. Epub 2012 Jun 4. J Clin Oncol. 2012. PMID: 22665533 Free PMC article. Clinical Trial.

10

Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ. Bose R, et al. Among authors: ma cx. Cancer Discov. 2013 Feb;3(2):224-37. doi: 10.1158/2159-8290.CD-12-0349. Epub 2012 Dec 7. Cancer Discov. 2013. PMID: 23220880 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

293 results

Search Page

Filters